Pyridoxal isonicotinoyl hydrazone
(Synonyms: PIH) 目录号 : GC13308
A lipophilic iron chelator
Cas No.:737-86-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Pyridoxal isonicotinoyl hydrazine is a cell-permeable and relatively non-toxic iron (Fe3+) chelator [1].
Pyridoxal isonicotinoyl hydrazone (PIH) is a tridentate Fe-chelating agent that shows high Fe chelation efficacy. In 59Fe-labeled reticulocytes, PIH (0.1 mmol/L) released 38.6% of cellular 59Fe [1]. PIH inhibited the formation of ascorbyl radical and Fe(III)–EDTA-mediated ascorbate oxidation in a dose-dependent way [3].
In Fe-loaded rats, PIH orally administrated resulted in an eightfold increase in fecal Fe excretion and possibly some urinary excretion of Fe [1]. In mice loaded with iron-acetohydroxamic acid complex, pyridoxal isonicotinoyl hydrazone (po.) were given daily for four days at 300 mg/kg/day. Total iron excreted over the 4-day period (micrograms/mouse) was 31 [2]. Pyridoxal isonicotinoyl hydrazine could be used for experimental chelating therapy in iron-overload diseases [3].
References:
[1].Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med. 1998 Apr;131(4):306-15.
[2].Gale GR, Litchenberg WH, Smith AB, et al. Comparative iron mobilizing actions of deferoxamine, 1,2-dimethyl-3-hydroxypyrid-4-one, and pyridoxal isonicotinoyl hydrazone in iron hydroxamate-loaded mice. Res Commun Chem Pathol Pharmacol. 1991 Sep;73(3):299-313.
[3].Maurício AQ, Lopes GK, Gomes CS, et al. Pyridoxal isonicotinoyl hydrazone inhibits iron-induced ascorbate oxidation and ascorbyl radical formation. Biochim Biophys Acta. 2003 Mar 17;1620(1-3):15-24.
| Cas No. | 737-86-0 | SDF | |
| 别名 | PIH | ||
| 化学名 | (E)-N'-((3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl)methylene)isonicotinohydrazide | ||
| Canonical SMILES | CC1=C(O)C(/C([H])=N/NC(C2=CC=NC=C2)=O)=C(CO)C=N1 | ||
| 分子式 | C14H14N4O3 | 分子量 | 286.29 |
| 溶解度 | ≥ 28.6mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.493 mL | 17.4648 mL | 34.9296 mL |
| 5 mM | 0.6986 mL | 3.493 mL | 6.9859 mL |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.493 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。